Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype. (2020)
Attributed to:
BAG-1: A novel strategy for targeting the androgen receptor splice variants in castrate resistant prostate cancer.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.annonc.2020.04.473
PubMed Identifier: 32387417
Publication URI: http://europepmc.org/abstract/MED/32387417
Type: Journal Article/Review
Volume: 31
Parent Publication: Annals of oncology : official journal of the European Society for Medical Oncology
Issue: 9
ISSN: 0923-7534